Research programme: RNA targeting small molecule therapeutics - ReviR Therapeutics
Latest Information Update: 30 Jul 2024
At a glance
- Originator ReviR Therapeutics
- Class Small molecules
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
- Research Charcot-Marie-Tooth disease; Huntington's disease